There’s a new FDA-approved melanoma medication on the scene. Today, the U.
Array Biopharma (NASDAQ:ARRY) shares started the day lower in the wake of disappointing results from competitor Exelixis (NASDAQ:EXEL). Exelixis announced that its metastatic colorectal cancer (mCRC) treatment did …
Array BioPharma (NASDAQ:ARRY) shares surged 81% yesterday after the firm conveyed promising phase 3 COLUMBUS results for its BRAF-mutant melanoma cancer treating pipeline …
In a research report published Monday, Cantor analyst Mara Goldstein maintained a Buy rating on Array Biopharma (NASDAQ:ARRY) with a $13 price target, …
